Funding for this trial has been provided in full or in part by Cystic Fibrosis Foundation Therapeutics, Inc.
Number of Participants Being Recruited:
Single / Multi-Center:
STUDY BACKGROUND INFORMATION:
Recent genetic studies have shown that CF patients with a variation in the gene for TGF-b1, a key regulator of immune function and tissue repair, are twice as likely to have severe lung disease. This study will examine if TGF-b1 is reduced when taking Azithromycin
>= 8 Years
>= 40 Percent Predicted
P. aeruginosa status:
B. cepacia status:
Other Primary Eligibility Requirements:
Note: Detailed eligibility criteria information may be available on clinicaltrials.gov. If a specific
trial listing for this trial is available, a link to the specific clinicaltrials.gov listing will be present in the "More Information" section below.
The sites listed below are currently recruiting subjects. Please note that this list generally lists either the pediatric or adult program but not both even though both programs may be recruiting subjects. Also, this list does not include sites that may be participating in the study but are not yet open for recruitment. If you are interested in this study please contact your center for more information.
University of North Carolina at Chapel Hill (Pediatric), Chapel Hill, NC, 27599
Barlow, Carol Phone: (919) 966-9146 Email: email@example.com